Skip to main content

Table 2 Correlations between calprotectin, and other clinical and metabolic parameters in diabetic patients

From: Is calprotectin a novel biomarker of neuroinflammation in diabetic periferal neuropathy?

 

BMI

SBP

DBP

HDL-C

LDL-C

TG

FBP

HbA1C

hsCRP

Calprotectin

         

R

0.147

0.061

0.135

−0.166

−0.028

0.192

0.221

0.437

0.510

P

0.177

0.577

0.215

0.129

0.796

0.077

0.041

<0.001

<0.001

BMI

         

R

 

0.237

0.146

0.097

0.126

−0.501

0.117

0.180

0.175

P

 

0.028

0.180

0.377

0.246

0.641

0.285

0.096

0.188

SBP

         

R

  

0.611

0.228

0.239

−0.051

0.003

0.112

−0.030

P

  

<0.001

0.036

0.027

0.641

0.982

0.303

0.823

DBP

         

R

   

0.259

0.155

−0.158

0.070

0.150

0.019

P

   

0.017

0.153

0.146

0.523

0.169

0.887

HDL-C

         

R

    

0.460

0.077

0.391

0.271

−0.224

P

    

<0.001

0.484

<0.001

0.012

0.094

LDL-C

         

R

     

0.171

0.224

0.070

−0.328

P

     

0.116

0.038

0.522

0.012

TG

         

R

      

0.587

0.324

−0.047

P

      

<0.001

0.002

0.726

FBG

         

R

       

0.729

0.207

P

       

<0.001

0.120

HbA1C

         

R

        

0.203

P

        

0.127

  1. Data were expressed as median (±IQR) and *mean (±SD). Mann–Whitney U and *Student’s t-test was used in comparison of 2 independent group. DM with neuropath group, DNP (+); DM without neuropathy group, DNP (−); Healthy control group, HC; Body Mass Index, BMI; Systolic blood pressure, SBP; Diastolic blood pressure; Fasting blood glucose; High density lipoprotein cholesterol, HDL-C; Triglyceride, TG; Low density lipoprotein cholesterol, LDL-C; High sensitive C reactive protein, hsCRP; Oral antidiabetic drug, OAD.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us